Pharmacological evaluation of Orai-1 inhibitor in 3-nitropropionic acid-induced Huntington disease
Journal of Pharmacy and Pharmacology · 03.04.2026 · 78 (4)
DOI: 10.1093/jpp/rgag030 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, online erschienen am 14.04.2026. Verfasst von Veerta Sharma und 2 weiteren Autor:innen. Beteiligte Einrichtung: Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab 140401, India. Hauptthemen laut MEDLINE: Huntington Disease, Neuroprotective Agents, ORAI1 Protein. Die Arbeit nennt 42 Literaturangaben.
Abstract (Originalsprache)
Objectives
Huntington’s disease (HD) is a neurodegenerative condition characterized by a gradual decline in motor skills, cognitive function, and mental health. The 3-nitropropionic acid (3-NPA) model simulates HD-like pathology, which involves calcium dysregulation. To establish a structural basis for targeting Orai-1, in-silico docking was conducted prior to assessing the neuroprotective effects of the Orai-1 inhibitor Synta-66 in a 3-NPA-induced HD model.
Methods
Mice were randomly divided into five groups (n = 8): normal control, 3-NPA (10 mg/kg, i.p.), 3-NPA combined with tetrabenazine (3 mg/kg, i.p.), 3-NPA combined with Synta-66 (5 mg/kg, i.p.), and 3-NPA combined with Synta-66 (10 mg/kg, i.p.). In-silico docking was used to evaluate the interactions of Synta-66 with Orai-1 and other targets related to neurodegeneration. Various parameters including behavioural, biochemical, oxidative stress, and neuroinflammatory markers were assessed. Additionally, the ELISA expression of Orai-1 protein and Ca2+ levels were measured. Key findings In-silico analysis revealed that Synta-66 binds effectively with Orai-1 and its related targets. In vivo studies showed that 3-NPA caused notable motor impairments, biochemical changes, neuroinflammation, and disruptions in Ca2+ regulation. Administration of Synta-66 led to a dose-dependent recovery of body weight, enhancement of behavioural performance, normalization of biochemical and neuroinflammatory indicators, and a decrease in Orai-1 protein levels and intracellular Ca2+ concentrations, similar to the effects of tetrabenazine.
Conclusion
The findings suggest the therapeutic potential of targeting Orai-1 channel using the inhibitor Synta-66 could serve as a neuroprotective treatment in a 3-NPA-induced HD model in mice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab 140401, India.
ORCID-Profile: Veerta Sharma, Shareen Singh, Thakur Gurjeet Singh
Zitieren
APA
Sharma, V., Singh, S., & Singh, T. G. (2026). Pharmacological evaluation of Orai-1 inhibitor in 3-nitropropionic acid-induced Huntington disease. Journal of Pharmacy and Pharmacology, 78(4). https://doi.org/10.1093/jpp/rgag030
Vancouver
Sharma V, Singh S, Singh TG. Pharmacological evaluation of Orai-1 inhibitor in 3-nitropropionic acid-induced Huntington disease. Journal of Pharmacy and Pharmacology. 2026;78(4). doi:10.1093/jpp/rgag030
BibTeX
@article{Sharma2026,
author = {Sharma, Veerta and Singh, Shareen and Singh, Thakur Gurjeet},
title = {Pharmacological evaluation of Orai-1 inhibitor in 3-nitropropionic acid-induced Huntington disease},
journal = {Journal of Pharmacy and Pharmacology},
year = {2026},
volume = {78},
number = {4},
doi = {10.1093/jpp/rgag030}
}
EUVIMED